Repligen Corporation (NASDAQ:RGEN - Get Free Report) shares were up 6.6% during mid-day trading on Wednesday. The company traded as high as $171.56 and last traded at $172.8110. 165,943 shares changed hands during trading, a decline of 84% from the average daily volume of 1,060,255 shares. The stock had previously closed at $162.18.
Wall Street Analysts Forecast Growth
RGEN has been the topic of a number of recent analyst reports. Zacks Research lowered Repligen from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 28th. Wells Fargo & Company boosted their target price on shares of Repligen from $180.00 to $185.00 and gave the company an "overweight" rating in a research note on Thursday, July 30th. Canaccord Genuity Group boosted their target price on shares of Repligen from $145.00 to $180.00 and gave the company a "hold" rating in a research note on Monday, October 19th. Barclays upped their price target on shares of Repligen from $175.00 to $225.00 and gave the stock an "overweight" rating in a report on Wednesday, October 7th. Finally, Royal Bank Of Canada raised their price target on shares of Repligen from $185.00 to $200.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 28th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $178.57.
Check Out Our Latest Stock Report on RGEN
Repligen Stock Performance
The stock has a market cap of $11.04 billion, a PE ratio of -826.03, a price-to-earnings-growth ratio of 2.79 and a beta of 1.11. The company has a quick ratio of 8.43, a current ratio of 9.88 and a debt-to-equity ratio of 0.27. The firm has a 50 day moving average price of $176.92 and a 200 day moving average price of $145.71.
Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share for the quarter, topping analysts' consensus estimates of $0.46 by $0.07. Repligen had a negative net margin of 1.47% and a positive return on equity of 5.49%. The company had revenue of $209.31 million during the quarter, compared to analyst estimates of $206.70 million. During the same period in the prior year, the firm earned $0.46 earnings per share. The firm's revenue for the quarter was up 10.9% compared to the same quarter last year. As a group, research analysts forecast that Repligen Corporation will post 2.07 earnings per share for the current year.
Hedge Funds Weigh In On Repligen
Institutional investors have recently bought and sold shares of the business. United Capital Financial Advisors LLC purchased a new stake in shares of Repligen during the second quarter valued at $380,756,000. William Blair Investment Management LLC raised its stake in Repligen by 57.7% in the 3rd quarter. William Blair Investment Management LLC now owns 1,243,415 shares of the biotechnology company's stock worth $239,022,000 after acquiring an additional 454,844 shares during the last quarter. Wasatch Advisors LP lifted its position in Repligen by 27.9% during the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company's stock worth $216,974,000 after acquiring an additional 346,720 shares during the period. Congress Asset Management Co. lifted its position in Repligen by 0.9% during the 3rd quarter. Congress Asset Management Co. now owns 1,020,907 shares of the biotechnology company's stock worth $196,249,000 after acquiring an additional 8,681 shares during the period. Finally, ABS Investment Management LLC acquired a new stake in Repligen during the 2nd quarter worth about $191,016,000. 97.64% of the stock is owned by hedge funds and other institutional investors.
About Repligen
(
Get Free Report)
Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company's offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.